Hsiao Lieu
Chief Tech/Sci/R&D Officer bij NGM BIOPHARMACEUTICALS, INC.
Vermogen: 55 499 $ op 31-03-2024
Profiel
Hsiao Dee Lieu is the founder of Retinorx LLC.
He is currently the Chief Medical Officer & Executive Vice President at NGM Biopharmaceuticals, Inc. and also holds the position of Adjunct Assistant Clinical Professor-Medicine at The University of California, San Francisco.
Previously, he worked as the Vice President & Managing Director-Chorus at Eli Lilly & Co., Director-Clinical Research & Development at CV Therapeutics, Inc., Director-Clinical Development at Portola Pharmaceuticals LLC, Vice President-Early Clinical Development at Genentech, Inc., and Executive Vice President-Clinical Development at Capricor Therapeutics, Inc. Dr. Lieu completed his undergraduate degree at New York University and obtained his doctorate degrees from Yeshiva University and Albert Einstein College of Medicine, Inc.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 05-04-2024 | 34 905 ( 0.04% ) | 55 499 $ | 31-03-2024 |
Actieve functies van Hsiao Lieu
| Bedrijven | Functie | Begin |
|---|---|---|
| NGM BIOPHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01-03-2019 |
| The University of California, San Francisco | Corporate Officer/Principal | - |
Eerdere bekende functies van Hsiao Lieu
| Bedrijven | Functie | Einde |
|---|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 01-03-2019 |
| PORTOLA PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01-01-2008 |
CV Therapeutics, Inc.
 CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | Chief Tech/Sci/R&D Officer | 01-01-2006 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
| Retinorx LLC | Chief Executive Officer | - |
Opleiding van Hsiao Lieu
| New York University | Undergraduate Degree |
| Yeshiva University | Doctorate Degree |
| Albert Einstein College of Medicine, Inc. | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| NGM BIOPHARMACEUTICALS, INC. | Health Technology |
| CAPRICOR THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | Health Technology |
Portola Pharmaceuticals LLC
 Portola Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Portola Pharmaceuticals, Inc. engaged in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA. | Health Technology |
| Retinorx LLC |
